8-K: Allurion Faces NYSE Delisting, Appeals Decision

Allurion Technologies, Inc. has been notified of delisting from the NYSE due to market capitalization non-compliance, but the company is appealing the decision and executing a plan to relist.

Summary

• Allurion Technologies, Inc. received a notice from the New York Stock Exchange (NYSE) on March 6, 2026, regarding the commencement of delisting proceedings for its common stock and warrants.
• The delisting is due to non-compliance with NYSE Rule 802.01B, which requires an average global market capitalization of at least $15 million over 30 consecutive trading days.
• Trading of Allurion's common stock on the NYSE was suspended after market close on March 6, 2026.
• The company has appealed the delisting determination and expects to trade on the OTCID Market under symbols "ALUR" and ALUR.WS during the appeal process.
• Allurion intends to apply to list on a higher-tier market operated by the OTC Market Group, Inc.
• The company has a detailed plan, catalyzed by its recent FDA approval of the Allurion Gastric Balloon System, to regain compliance with NYSE listing standards or relist on the NYSE American, strengthen its balance sheet, and fund U.S. commercialization of the Allurion Smart Capsule.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative event due to the NYSE delisting and trading suspension, which raises concerns about investor confidence and market liquidity. While the FDA approval and a plan to relist offer a glimmer of hope, the immediate impact is adverse.

Positives

• Recent FDA approval of the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, on February 20, 2026.
• Company has a detailed plan to regain compliance with NYSE listing standards or relist on the NYSE American.
• Management expresses confidence in executing the plan to capitalize on U.S. FDA approval and address the obesity market.
• The transition to the OTCID Market is not expected to affect business operations or current SEC reporting obligations.

Negatives

• NYSE initiated delisting proceedings against Allurion's common stock and warrants.
• Trading of Allurion's common stock on the NYSE was suspended on March 6, 2026.
• The company failed to maintain an average global market capitalization of at least $15 million over 30 consecutive trading days.
• There is no assurance that the appeal will be successful or that the company will be able to relist on a national exchange.
• Uncertainty regarding continued trading on the OTCID Market, broker-dealer quotes, or sufficient trading volume for an efficient market.

Risks

• Inability to maintain regulatory approvals for and successfully commercialize products, including the Allurion Balloon.
• Uncertainty regarding the timing and results from clinical studies and trials.
• Evolution of the markets in which the company competes, including the impact of GLP-1 drugs.
• Inability to defend intellectual property and satisfy regulatory requirements.
• Impact of global economic conditions and geopolitical events on the company's business.
• Risk of economic downturns and a changing regulatory landscape in the highly competitive industry.
• The delisting notice and noncompliance with NYSE continued listing standards may impact the company's results of operations, business operations, reputation, and the trading prices and volatility of its common stock.
• Inability to regain compliance with NYSE continued listing standards or to satisfy the initial listing standards of another nationally recognized securities exchange.
• Inability to complete a transaction or transactions to achieve compliance with exchange requirements on acceptable terms, or at all.

Future Outlook

Allurion intends to appeal the delisting decision and execute a detailed plan to regain compliance with NYSE listing standards or relist on the NYSE American. This plan is focused on leveraging recent FDA approval to strengthen the balance sheet and fund U.S. commercialization of the Allurion Smart Capsule, aiming to address the significant market of Americans suffering from obesity.

Management Comments

• "We have been in regular contact with the NYSE about our step-by-step plan to regain compliance with its listing standards or initiate listing on the NYSE American." Dr. Shantanu Gaur, Founder and Chief Executive Officer.
• "The first step in our plan was receiving FDA approval, which was received on February 20, 2026. We are leveraging this approval to touch off the remaining parts of our plan to ultimately regain compliance or relist." Dr. Shantanu Gaur, Founder and Chief Executive Officer.
• "We are confident we can execute this plan, setting up Allurion to capitalize on our U.S. FDA approval and enabling us to treat the more than 100 million Americans suffering from obesity, 20 million of whom have already tried a GLP-1 but discontinued use." Dr. Shantanu Gaur, Founder and Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Allurion operates in the competitive weight loss market, which is currently experiencing significant disruption and growth, partly due to the rise of GLP-1 drugs. The company's focus on the Allurion Gastric Balloon System, particularly for the 20 million Americans who have discontinued GLP-1 use, positions it to target a specific segment within this evolving landscape. The FDA approval is a critical step for U.S. market penetration, but the delisting adds a layer of uncertainty regarding investor confidence and access to capital compared to more stable, larger players in the health and wellness sector.

Comparison to Industry Standards

• Allurion's market capitalization falling below the NYSE's $15 million threshold indicates a significant underperformance compared to established medical device or biotechnology companies listed on major exchanges.
• The company's strategy to target individuals who have discontinued GLP-1 use positions it against pharmaceutical giants like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Zepbound, Mounjaro), which dominate the GLP-1 market. Allurion's non-invasive balloon system offers an alternative, but its commercial success will depend on demonstrating superior outcomes or cost-effectiveness for its target demographic compared to these highly effective drug therapies.
• Relisting on a higher-tier OTC market or NYSE American would place Allurion among smaller-cap companies, often with higher risk profiles, rather than the larger, more liquid companies typically found on the main NYSE.

Legal Proceedings

• Appeal of the NYSE's delisting determination.

Stakeholder Impact

• Shareholders: Immediate negative impact due to NYSE delisting, trading suspension, and transition to OTCID Market, potentially leading to reduced liquidity and price volatility. Uncertainty regarding future listing status.
• Employees: No direct impact on business operations mentioned, but delisting can create uncertainty and affect morale.
• Customers: No direct impact on product availability or service.
• Creditors: Potential concerns regarding the company's financial stability and ability to raise capital, which could affect credit terms.

Next Steps

• Company's appeal of the NYSE delisting determination.
• Application to list on a higher-tier market operated by the OTC Market Group, Inc.
• Execution of the detailed plan to regain compliance with NYSE listing standards or relist on the NYSE American.
• Strengthening the balance sheet.
• Funding commercialization of the Allurion Smart Capsule in the U.S.

Key Dates

Recommendation

The NYSE delisting and trading suspension are severe negative events that significantly impair liquidity and investor confidence. While the company has an appeal and a plan, the uncertainty of success and the immediate move to the OTC market present substantial risks. Investors should consider selling to avoid further potential losses and reduced market access.

Keywords

Allurion Technologies, NYSE delisting, market capitalization, OTCID Market, FDA approval, Allurion Gastric Balloon, Allurion Smart Capsule, obesity treatment, weight loss, corporate governance, stock exchange, listing standards